BiomX Q2 2026 Earnings Results & Report

BiomX EPS Results

• Actual EPS: -$3.70
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 0 of last 4 quarters

BiomX Revenue Results

• Actual Revenue: $0.33 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

BiomX (NYSEAMERICAN:PHGE) is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies. Its approach uses naturally occurring viruses, known as phages, to selectively identify and destroy harmful bacteria while seeking to preserve beneficial microorganisms in the microbiome.

The company’s lead program, BX004, is an inhaled phage therapy designed to target Pseudomonas aeruginosa, a bacterium associated with chronic lung infections in people with cystic fibrosis. BiomX has also developed additional phage-based programs aimed at bacterial infections and microbiome-related diseases, including gastrointestinal conditions. The company’s therapies are investigational and remain subject to clinical testing and regulatory review.

BiomX was founded in Israel and has advanced its development programs through clinical studies conducted in the United States and other locations. The company became publicly traded following a business combination with Chardan Healthcare Acquisition Corp. in 2019. BiomX’s operations are centered on research, clinical development and potential commercialization of precision antibacterial therapies.